Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Bradley Hiatt (NPI 1841254406)

Field	Value
Entity Type	Individual
Organization	Bradley Hiatt
Address	411 Laurel St Ste A300
City	Des Moines
State	IA
ZIP	50314
Taxonomy	Medical Oncology Physician
NPI Enumerated	April 12, 2006

Payer Source	Total Paid
Medicare	$2.2M
Medicaid	$0

Key Findings

This provider is effectively single‑payer in the datasets available: lifetime Medicare revenue is $2.2M while there is no Medicaid billing on file, so all billed public-payer activity in the record is Medicare-driven. That concentration means any analysis of patient mix or revenue risk should treat Medicare as the dominant and sole public-payer exposure represented here.

Revenue is highly concentrated in a few injectable oncology agents: the precomputed top 3 Medicare codes account for 60.4% of total Medicare revenue, driven primarily by J9271 ($739.6K, 33.8%), J9144 ($335.2K, 15.3%), and J9299 ($246.5K, 11.3%). This concentration indicates that a small number of high-cost biologic therapies are the primary revenue drivers for the practice.

The code mix points to a medical‑oncology infusion center focused on immuno‑oncology and hematologic agents. High-revenue J‑codes such as J9271 (pembrolizumab), J9144 (daratumumab), and J9299 (nivolumab), together with supportive agents like J0897 (denosumab) and J2506 (pegfilgrastim), are consistent with treatment of solid tumors and plasma‑cell malignancies and routine in‑office administration of biologic therapies.

Competitive standing on the top immunotherapy agents is modest to typical nationally: J9271 ranks #541 of 1841 (70th percentile; typical, unremarkable volume), J9144 ranks #276 of 615 (54th percentile; typical, unremarkable), and J9299 ranks #309 of 505 (39th percentile; typical, unremarkable). Those ranks suggest the provider is not a national leader in any single immunotherapy but is a regular regional participant in these high-cost agents.

Several non‑drug E/M and infusion administration codes are statistical outliers in terms of volume, indicating above‑typical visit and infusion throughput. Notably, 99214 is an extreme outlier (ranks #6215 of 479517 providers nationally, 99th percentile; extreme outlier, far above typical national volume) and accounts for $113.4K (5.2%) of Medicare revenue, while 99213 ($34.7K, 1.6%) and 99205 ($21.1K, 1.0%) are also listed as notably above typical; this pattern implies substantial office-based clinical contact and documentation intensity tied to infusion care.

There is evidence of significant in‑office supportive services and high infusion throughput beyond specialty biologics: chemotherapy administration 96413 ($50.9K, 2.3%) ranks #562 of 7514 (92th percentile; notably above typical), add‑on infusion 96367 ($14.5K, 0.7%) ranks in the 95th percentile, and basic lab/support codes such as 80053 ($12.6K) and 85025 ($11.1K) sit at the 96th and 95th percentiles respectively. Together these codes and percentiles support an operational model that combines drug administration with on-site monitoring and lab work rather than a referral‑only model.

Biosimilar utilization shows mixed but notable adoption in some agents: Q5118 (bevacizumab‑bvzr) contributes $120K (5.5%) and ranks #21 of 161 (88th percentile; typical, unremarkable volume), while Q5126 (bevacizumab‑maly) and Q5115 (rituximab‑abbs) appear in smaller volumes ($88.7K and $73.9K respectively) with lower national percentiles. This suggests selective use of biosimilars in practice inventory and patients, with particularly strong relative utilization of one bevacizumab biosimilar compared with peers.

The provider has a long tenure in the NPI file (NPI enumerated 2006-04-12, ~20 years ago), which, combined with a $2.2M lifetime Medicare revenue profile and a drug‑heavy code mix, points to a sustained, focused oncology practice serving Medicare beneficiaries over an extended period. Given the single‑payer Medicare exposure and concentrated revenue in a handful of biologics, payers and provider analysts should consider how drug pricing, biosimilar adoption, and shifts in oncology care pathways could materially affect this provider's revenue profile.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

70 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	17,200	$40	$739.6K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	8,820	$40	$335.2K
J9299	Injection, nivolumab, 1 mg	11,740	$20	$246.5K
J0897	Injection, denosumab, 1 mg	9,300	$20	$167.4K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	4,800	$30	$120K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,260	$90	$113.4K
Q5126	Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg	1,740	$50	$88.7K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	2,110	$40	$73.8K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	680	$80	$52K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	540	$90	$50.9K

Showing 1–10 of 70

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 70 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Bradley Hiatt — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

70 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	14	30	17,200	$40	$902.3K
J9299	6	10	18,700	$20	$527.6K
J9144	5	10	9,900	$40	$476.8K
Q5126	3	10	3,270	$50	$146.6K
Q5118	3	10	5,840	$20	$137.4K
J0897	21	190	1,920	$20	$74.1K
Q5115	4	10	1,790	$30	$71.4K
J2506	4	20	440	$80	$38.9K
96413	9	80	210	$90	$24K
J9217	33	50	140	$130	$23.4K

Showing 1–10 of 70

Related Providers

Other providers that share a Tax Identification Number (TIN) with Bradley Hiatt, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Broadlawns Medical Center	IA	General Acute Care Hospital	$0	$112.9M
State University Of Iowa	IA	Family Medicine Physician	$0	$103.8M
State University Of Iowa	IA	General Acute Care Hospital	$0	$90.4M
State University Of Iowa	IA	Dentist	$0	$25.8M
Broadlawns Medical Center	IA	Community/Behavioral Health Agency	$0	$13.2M
Thomas Buroker	IA	Medical Oncology Physician	$9.4M	$0
Kyle Alliman	IA	Ophthalmology Physician	$8.7M	$0
Alex Kartvelishvili	IA	Ophthalmology Physician	$8.1M	$0
Paul Boeke	IA	Ophthalmology Physician	$7.1M	$0
Austin Strohbehn	IA	Retina Specialist (Ophthalmology) Physician	$5.8M	$0

Nearby Providers

Other providers in the same ZIP code as Bradley Hiatt, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Catholic Health Initiatives-iowa Corp	IA	General Acute Care Hospital	$0	$26.4M
Des Moines Independent Community School District	IA	Local Education Agency (LEA)	$0	$22.8M
Primary Health Care, Inc.	IA	Federally Qualified Health Center (FQHC)	$0	$14.1M
Mercy Clinics Inc	IA	Pediatric Adolescent Medicine Physician	$0	$10.7M
Des Moines River Physicians, LLC	IA	Emergency Medicine Physician	$0	$8.1M
Catholic Health Initiatives-iowa Corp	IA	Clinical Medical Laboratory	$0	$8M
Primary Health Care, Inc.	IA	Federally Qualified Health Center (FQHC)	$0	$7.9M
Vita Health Services	IA	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$7.5M
House Of Mercy	IA	Substance Abuse Rehabilitation Facility	$0	$7.4M
Primary Health Care, Inc.	IA	Federally Qualified Health Center (FQHC)	$0	$7.2M

Bradley Hiatt — Billing Profile & Reimbursement Data

Sign up for Bradley Hiatt — Billing Profile & Reimbursement Data policy alerts

Bradley Hiatt — Billing Profile & Reimbursement Data

Sign up for Bradley Hiatt — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References